Pectin Matrix as Oral Drug Delivery Vehicle for Colon Cancer Treatment

详细信息    查看全文

• 作者：Tin Wui Wong (1) (2) (5)
  Gaia Colombo (3)
  Fabio Sonvico (4)
  
• 关键词：colon cancer ; oral drug delivery ; pectin
• 刊名：AAPS PharmSciTech
• 出版年：2011
• 出版时间：March 2011
• 年：2011
• 卷：12
• 期：1
• 页码：201-214
• 全文大小：391KB
• 参考文献：1. Watts PJ, Illum L. Colonic drug delivery. Drug Dev Ind Pharm. 1997;23(9):893鈥?13.
  2. Vandamme ThF, Lenourry A, Charrueau C, Chaumeil J-C. The use of polysaccharides to target drugs to the colon. Carbohydr Polym. 2002;48:219鈥?1.
  3. Byrd JC, Bresalier RS. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev. 2004;23:77鈥?9.
  4. Singh BN. Modified release solid formulations for colonic delivery. Recent Pat Drug Deliv Formul. 2007;1:53鈥?3.
  5. Yang L. Biorelevant dissolution testing of colon-specific delivery systems activated by colonic microflora. J Control Release. 2008;125:77鈥?6.
  6. Sinha VR, Kumria R. Microbially triggered drug delivery to the colon. Eur J Pharm Sci. 2003;18:3鈥?8.
  7. Guarner F. Enteric flora in health and disease. Digestion. 2006;73 suppl 1:5鈥?2.
  8. World Health Organization: Health topics. http://www.who.int/topics/cancer/en (2009). Accessed 25 Feb 2009.
  9. Boyle P, Leon ME. Recent developments in the epidemiology of colorectal cancer. In: Bleiberg H, Kemeny N, Rougier P, Wilke H, editors. Colorectal cancer鈥?A clinical guide to therapy, chapter 2. UK: Taylor and Francis; 2002. p. 11鈥?9.
  10. Lieberman D. Colorectal cancer screening and surveillance. In: Ginsberg GG, Kochman ML, Norton I, Gostout CJ, editors. Clinical gastrointestinal endoscopy, Chapter 37. UK: Elservier; 2005. p. 537鈥?7.
  11. Midgley RS, Merrie A, Kerr DJ, Mortensen N. Colorectal cancer: a multidisciplinary approach. In: Weinstein WM, Hawkey CJ, Bosch J, editors. Clinical gastroenterology and hepatology, Chapter 60D. Spain: Elsevier; 2005. p. 421鈥?0.
  12. Johnson IT. New approaches to the role of diet in the prevention of cancers of the alimentary tract. Mutat Res. 2004;551:9鈥?8.
  13. Yen EF. Colon neoplasms. In: Shiels A, Lin TL, editors. The Washington ManualTM gastroenterology subspecialty consult, Chapter 17. USA: Lippincott Williams & Wilkins; 2004. p. 93鈥?00.
  14. Soetikno R, Friedland S, Matsuda T, Gotoda T. Colonoscopic polypectomy and endoscopic mucosal resection. In: Ginsberg GG, Kochman ML, Norton I, Gostout CJ, editors. Clinical gastrointestinal endoscopy, Chapter 38. UK: Elservier; 2005. p. 549鈥?8.
  15. Wikipedia. Colorectal cancer. Wikipedia: the free Encyclopedia. Accessed 17 Apr 2009.
  16. Greenwald P, Clifford CK, Milner JA. Diet and cancer prevention. Eur J Cancer. 2001;37:948鈥?5.
  17. Benamouzig R. Chemoprevention of colorectal cancer. In: Bleiberg H, Kemeny N, Rougier P, Wilke H, editors. Colorectal cancer鈥?A clinical guide to therapy, chapter 5. UK: Taylor and Francis; 2002. p. 47鈥?2.
  18. Watson AJM. An overview of apoptosis and the prevention of colorectal cancer. Crit Rev Oncol Hematol. 2006;57:107鈥?1.
  19. Strate L, Pieramici E, Ahnen D. Biology and genetics of colorectal cancer. In: Weinstein WM, Hawkey CJ, Bosch J, editors. Clinical gastroenterology and hepatology, Chapter 60A. Spain: Elsevier; 2005. p. 397鈥?06.
  20. Abramowicz MJ. Biology of colorectal cancer: an overview of genetic factors. In: Bleiberg H, Kemeny N, Rougier P, Wilke H, editors. Colorectal cancer鈥攁 clinical guide to therapy, chapter 1. UK: Taylor and Francis; 2002. p. 3鈥?.
  21. Liu C, Crawford JM. The gastrointestinal tract. In: Kumar V, Abbas AK, Fausto N, editors. Pathologic basis of disease, Chapter 17. USA: Elsevier; 2005. p. 797鈥?75.
  22. Hermanek P. Pathology of colorectal cancer. In: Bleiberg H, Kemeny N, Rougier P, Wilke H, editors. Colorectal cancer鈥?A clinical guide to therapy. UK: Taylor and Francis; 2002. p. 55鈥?2.
  23. Davies JM, Goldberg RM. First-line therapeutic strategies in metastatic colorectal cancer. Oncol Huntingt. 2008;22:1470鈥?.
  24. Midgley R. Systemic adjuvant therapy of colon cancer. In: Bleiberg H, Kemeny N, Rougier P, Wilke H, editors. Colorectal cancer鈥攁 clinical guide to therapy, Chapter 12. UK: Taylor and Francis; 2002. p. 127鈥?4.
  25. Ammori JB, Kemeny NE. Regional hepatic chemotherapies in treatment of colorectal cancer metastases to the liver. Semin Oncol. 2010;37:139鈥?8.
  26. Sakamoto J, Oba K, Matsui T, Kobayashi M. Efficacy of oral anticancer agents for colorectal cancer. Dis Colon Rectum. 2006;49:S82鈥?1.
  27. National Cancer Institute, US National Institute of Health. Colon cancer treatment (PDQ庐). http://www.cancer.gov/cancertopics/pdq/treatment/colon/HealthProfessional/69.cdr. Accessed 27 July 2010.
  28. Ugurlu T, Turkoglu M, Gurer US, Akarsu BG. Colonic delivery of compression coated nisin tablets using pectin/HPMC polymer mixture. Eur J Pharm Biopharm. 2007;67:202鈥?0.
  29. Sinha VR, Kumria R. Polysaccharides in colon specific drug delivery. Int J Pharm. 2001;224:19鈥?8.
  30. Yang L, Chu JS, Fix JA. Colon-specific drug delivery, new approaches and / in vitro/ / in vivo evaluation. Int J Pharm. 2002;235:1鈥?5.
  31. Van den Mooter G, Maris B, Samyn C, Augustijns P, Kinget R. Use of azopolymers for colon specific drug delivery. J Pharm Sci. 1997;86:1321鈥?.
  32. Sinha VR, Kumria R. Coating polymers for colon specific drug delivery: a comparative / in vitro evaluation. Acta Pharm. 2003;53:41鈥?.
  33. Gazzaniga A, Maroni A, Sangalli ME, Zema L. Time-controlled oral delivery systems for colon targeting. Expert Opin Drug Deliv. 2006;3:583鈥?7.
  34. Shibata N, Ohno T, Shimokawa T, Hu Z, Yoshikawa Y, Koga K, / et al. Application of pressure-controlled colon delivery capsule to oral administration of glycyrrhizin in dogs. J Pharm Pharmacol. 2001;53:441鈥?.
  35. Liu CS, Fishman ML, Hicks KB. Pectin in controlled drug delivery鈥攁 review. Cellulose. 2007;14:15鈥?4.
  36. Liu LS, Fishman ML, Kost J, Hicks KB. Pectin-based systems for colon-specific drug delivery via oral route. Biomaterials. 2003;24:3333鈥?3.
  37. May CD. Pectins. In: Phillips GO, Williams PA, editors. Handbook of hydrocolloids, Chapter 10. UK: Woodhead Publishing Limited; 2003. p. 169鈥?8.
  38. Ridley BL, O鈥橬eill MA, Mohnen D. Pectins: structure, biosynthesis, and oligogalacturonide-related signaling. Phytochem. 2001;57:929鈥?7.
  39. Denev P. Kratchanov Chr. Influence of some cations on the reaction of apple pectin with ammonia in homogeneous media. In: Visser J, Voragen AGJ, editors. Pectins and pectinases. Amsterdam: Elsevier; 1996. p. 527鈥?0.
  40. Rinaudo M. Physicochemical properties of pectins in solution and gel states. In: Visser J, Voragen AGJ, editors. Pectins and pectinases. Amsterdam: Elsevier; 1996. p. 21鈥?3.
  41. Sriamornsak P. Chemistry of pectin and its pharmaceutical uses: a review. Silpakorn Uni Int J. 2003;3(1鈥?):206鈥?8.
  42. Moore MA, Park CB, Tsuda H. Soluble and insoluble fiber influences on cancer development. Crit Rev Oncol Hematol. 1998;27:229鈥?2.
  43. Lupton JR. Is fiber protective against colon cancer? Where the research is leading us. Nutrition. 2000;16(7/8):558鈥?1.
  44. Wong JM, de Souza R, Kendall CW, Emam A, Jenkins DJ. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol. 2006;40:235鈥?3.
  45. Ferguson LR, Harris PJ. Studies on the role of specific dietary fibres in protection against colorectal cancer. Mutat Res. 1996;350:173鈥?4.
  46. Park HS, Choi JS, Kim KH. Docosahexaenoic acid-rich fish oil and pectin have a hypolipidemic effect, but pectin increases risk factor for colon cancer in rats. Nutr Res. 2000;20(12):1783鈥?4.
  47. Bauer HG, Asp NG, Oste R. Effect of dietary fiber on the induction of colorectal tumors and fecal 尾-glucuronidase activity in the rat. Cancer Res. 1979;39(9):3752鈥?.
  48. Bauer HG, Asp NG, Dahigvist A. Effect of two kinds of pectin and guar gum on 1, 2-dimethylhydrazine initiation of colon tumors and on fecal 尾-glucuronidase activity in the rat. Cancer Res. 1981;41(6):2518鈥?3.
  49. Ohkami H, Tazawa K, Yamashita I, Shimizu T, Murai K, Kobashi K, / et al. Effects of apple pectin on fecal bacterial enzymes in azoxymethane-induced rat colon carcinogenesis. Jpn J Cancer Res. 1995;86(6):523鈥?.
  50. Tazawa K, Okami H, Yamashita I, Ohnishi Y, Kobashi K, Fujimaki M. Anticarcinogenic action of apple pectin on fecal enzyme activities and mucosal or portal prostaglandin E2 levels in experimental rat colon carcinogenesis. J Exp Clin Cancer Res. 1997;16(1):33鈥?.
  51. Olano-Martin E, Rimbach GH, Gibson GR, Rastall RA. Pectin and pecticoligosaccharides induce apoptosis in / in vitro human colonic adenocarcinoma cells. Anticancer Res. 2003;23(1A):341鈥?.
  52. Heitman DW, Hardman WE, Cameron IL. Dietary supplementation with pectin and guar gum on 1, 2-dimethylhydrazine-induced colon carcinogenesis in rats. Carcinogenesis. 1992;13(5):815鈥?.
  53. Umar S, Morris AP, Kourouma F, Sellin JH. Dietary pectin and calcium inhibit colonic proliferation / in vivo by differing mechanisms. Cell Prolif. 2003;36(6):361鈥?5.
  54. Nakahara S, Raz A. Regulation of cancer-related gene expression by galectin-3 and the molecular mechanism of its nuclear import pathway. Cancer Metastasis Rev. 2007;26:605鈥?0.
  55. Jacobasch G, Dongowski G, Florian S, M眉ller-Schmehl K, Raab B, Schmiedl D. Pectin does not inhibit intestinal carcinogenesis in APC-deficient Min/+ mice. J Agri Food Chem. 2008;56(4):1501鈥?0.
  56. Glinsky VV, Raz A. Modified citrus pectin anti-metastatic properties: one bullet, multiple targets. Carbohydr Res. 2009;344:1788鈥?1.
  57. Hayashi A, Gillen AC, Lott JR. Effects of daily oral administration of quercetin chalcone and modified citrus pectin on implanted colon-25 tumour growth in balb-c mice. Altern Med Rev. 2000;5(6):546鈥?2.
  58. Nangia-Makker P, Hogan V, Honjo Y, Baccarini S, Tait L, Bresalier R, / et al. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst. 2002;94(24):1854鈥?2.
  59. Thirawong N, Nunthanid J, Puttipipatkhachorn S, Sriamornsak P. Mucoadhesive properties of various pectins on gastrointestinal mucosa: an / in vitro evaluation using texture analyzer. Eur J Pharm Biopharm. 2007;67:132鈥?0.
  60. Liu LS, Fishman ML, Hicks KB, Kende M. Intercation of various pectin formulations with porcine colonic tissues. Biomaterials. 2005;26:5907鈥?6.
  61. Dongowski G, Anger H. Metabolism of pectin in the gastrointestinal tract. In: Visser J, Voragen AGJ, editors. Pectins and pectinases. Amsterdam: Elsevier; 1996. p. 659鈥?6.
  62. Saito D, Nakaji S, Fukuda S, Shimoyama T, Sakamoto J, Sugawara K. Comparison of the amount of pectin in the human terminal ileum with the amount of orally administered pectin. Nutrition. 2005;21:914鈥?.
  63. Ashford M, Fell J, Attwood D, Sharma H, Woodhead P. Studies on pectin formulations for colonic drug delivery. J Control Release. 1994;30:225鈥?2.
  64. Wei X, Sun N, Wu B, Yin C, Wu W. Sigmoidal release of indomethacin from pectin matrix tablets: Effect of / in situ crosslinking by calcium cations. Int J Pharm. 2006;318:132鈥?.
  65. Rubinstein A, Radai R, Ezra M, Pathak S, Rokem JS. / In vitro evaluation of calcium pectinate: a potential colon-specific drug delivery carrier. Pharm Res. 1993;10(2):258鈥?3.
  66. Wu B, Deng D, Lu Y, Wu W. Biphasic release of indomethacin from HPMC/pectin/calcium matrix tablet: II. Influencing variables, stability and pharmacokinetics in dogs. Eur J Pharm Biopharm. 2008;69:294鈥?02.
  67. El-Gibaly I. Oral delayed-release system based on Zn-pectinate gel (ZPG) microparticles as an alternative carrier to calcium pectinate beads for colonic drug delivery. Int J Pharm. 2002;232:199鈥?11.
  68. Adkin DA, Kenyon CJ. Itzhack Lerner E, Landau I, Strauss E, Caron D, Penhasi A, Rubinstein A, Wilding IR. The use of scintigraphy to provide 鈥減roof of concept鈥?for novel polysaccharide preparations designed for colonic drug delivery. Pharm Res. 1997;14(1):103鈥?.
  69. Ahrabi SF, Madsen G, Dyrstad K, Sande SA, Graffner C. Development of pectin matrix tablets for colonic delivery of model drug ropivacaine. Eur J Pharm Sci. 2000;10:43鈥?2.
  70. Wakerly Z, Fell JT, Attwood D, Parkins DA. / In vitro evaluation of pectin-based colonic drug delivery systems. Int J Pharm. 1996;129:73鈥?.
  71. Turkoglu M, Ugurlu T. / In vitro evaluation of pectin-HPMC compression coated 5-aminosalicylic acid tablets for colonic delivery. Eur J Pharm Biopharm. 2002;53:65鈥?3.
  72. Macleod GS, Fell JT, Collett JH. An / in vitro investigation into the potential for bimodal drug release from pectin/chitosan/HPMC-coated tablets. Int J Pharm. 1999;188:11鈥?.
  73. Ofori-Kwakye K, Fell JT. Biphasic drug release from film-coated tablets. Int J Pharm. 2003;250:431鈥?0.
  74. Ofori-Kwakye K, Fell JT, Sharma HL, Smith A-M. Gamma scintigraphic evaluation of film-coated tablets intended for colonic or biphasic release. Int J Pharm. 2004;270:307鈥?3.
  75. Wakerly Z, Fell JT, Attwood D, Parkins D. Studies on drug release from pectin/ethylcellulose film-coated tablets: a potential colonic delivery system. Int J Pharm. 1997;153:219鈥?4.
  76. Fern谩ndez-Herv谩s MJ, Fell JT. Pectin/chitosan mixtures as coatings for colon-specific drug delivery: an / in vitro evaluation. Int J Pharm. 1998;169:115鈥?.
  77. Chambin O, Dupuis G, Champion D, Voilley A, Pourcelot Y. Colon-specific drug delivery: influence of solution reticulation properties upon pectin beads performance. Int J Pharm. 2006;321:86鈥?3.
  78. Dupuis G, Chambin O, G茅nelot C, Champion D, Pourcelot Y. Colonic drug delivery: influence of crosslinking agent on pectin beads properties and role of the shell capsule type. Drug Dev Ind Pharm. 2006;32(7):847鈥?5.
  79. Bourgeois S, Gernet M, Pradeau D, Andremont A, Fattal E. Evaluation of critical formulation parameters influencing the bioactivity of 尾-lactamases entrapped in pectin beads. Int J Pharm. 2006;324:2鈥?.
  80. Chaurasia M, Chourasia MK, Jain NK, Jain A, Soni V, Gupta Y, / et al. Methotrexate bearing calcium pectinate microspheres: a platform to achieve colon-specific drug release. Curr Drug Deliv. 2008;5(3):215鈥?.
  81. Munjeri O, Collett JH, Fell JT. Hydrogel beads based on amidated pectins for colon-specific drug delivery: the role of chitosan in modifying drug release. J Control Release. 1997;46:273鈥?.
  82. Chang KLB, Lin J. Swelling behavior and the release of protein from chitosan-pectin composite particles. Carbohydr Polym. 2000;43:163鈥?.
  83. Hiorth M, Versland T, Heikkil盲 J, Tho I, Sande SA. Immersion coating of pellets with calcium pectinate and chitosan. Int J Pharm. 2006;308:25鈥?2.
  84. Wei H, Qing D, De-Ying C, Bai X, Li-Fang F. Pectin/ethylcellulose as film coatings for colon-specific drug delivery: Preparation and / in vitro evaluation using 5-fluorouracil pellets. PDA J Pharm Sci Technol. 2007;61(2):121鈥?0.
  85. Wei H, Qing D, De-Ying C, Bai X, Li-Fang F. Study on colon-specific pectin/ethylcellulose film-coated 5-fluorouracil pellets in rats. Int J Pharm. 2008;348:35鈥?5.
  86. Semd茅 R, Amighi K, Devleeschouwer MJ, Mo毛s AJ. Studies of pectin HM/Eudragit^庐 RL/Eudragit^庐 NE film-coating formulations intended for colonic drug delivery. Int J Pharm. 2000;197:181鈥?2.
  87. Semd茅 R, Amighi K, Devleeschouwer MJ, Mo毛s AJ. Effect of pectinolytic enzymes on the theophylline release from pellets coated with water insoluble polymers containing pectin HM or calcium pectinate. Int J Pharm. 2000;197:169鈥?9.
  88. Maestrelli F, Cirri M, Corti G, Mennini N, Mura P. Development of enteric-coated calcium pectinate microspheres intended for colonic drug delivery. Eur J Pharm Biopharm. 2008;69:508鈥?8.
  89. Chan WA, Boswell CD, Zhang Z. Comparison of the release profiles of a water soluble drug carried by Eudragit-coated capsules in different / in-vitro dissolution liquids. Powder Technol. 2001;119:26鈥?2.
  90. Jain A, Gupta Y, Jain SK. Potential of calcium pectinate beads for target specific drug release to colon. J Drug Targeting. 2007;15(4):285鈥?4.
  91. Paharia A, Yadav AK, Rai G, Jain SK, Pancholi SS, Agrawal GP. Eudragit-coated pectin microspheres of 5-fluorouracil for colon targeting. AAPS Pharm Sci Tech. 2007;8(1):Article 12 E1鈥?E7.
  92. Atyabi F, Majzoob S, Iman M, Salehi M, Dorkoosh F. / In vitro evaluation and modification of pectinate gel beads containing trimethyl chitosan, as a multi-particulate system for delivery of water-soluble macromolecules to colon. Carbohydr Polym. 2005;61(1):39鈥?1.
  93. Xi MM, Zhang SQ, Wang XY, Fang KQ, Gu Y. Study on the characteristics of pectin-ketoprofen for colon targeting in rats. Int J Pharm. 2005;298:91鈥?.
  94. Wang Q-W, Liu X-Y, Liu L, Feng J, Li Y-H, Guo Z-J, / et al. Synthesis and evaluation of the 5-fluorouracil-pectin conjugate targeted at the colon. Med Chem Res. 2007;16:370鈥?.
  95. Semd茅 R, Amighi K, Pierre D, Devleeschouwer MJ, Mo毛s AJ. Leaching of pectin from mixed pectin/insoluble polymer films intended for colonic drug delivery. Int J Pharm. 1998;174:233鈥?1.
  96. Hiorth M, Tho I, Sande SA. The formation and permeability of drugs across free pectin and chitosan films prepared by a spraying method. Eur J Pharm Biopharm. 2003;56:175鈥?2.
  97. Shike M. Diet and lifestyle in the prevention of colorectal cancer: an overview. Excerpta Med. 1999;106(1A):11S鈥?S.
  98. Alabaster O, Tang Z, Shivapurkar N. Dietary fiber and the chemopreventive modelation of colon carcinogenesis. Mutat Res. 1996;350:185鈥?7.
  99. Guarner F, Malagelada J-R. Gut flora in health and disease. Lancet. 2003;361(9356):512鈥?.
  100. Oscar C, Thompson-Chagoy谩n OC, Maldonado J, Gil A. Colonization and impact of disease and other factors of intestinal microbiota. Dig Dis Sci. 2007;52:2069鈥?7.
  101. Charalambides D, Segal I. Colonic pH: a comparison between patients with colostomies due to trauma and colorectal cancer. Am J Gastroenterol. 1992;87(1):74鈥?.
  102. McDougall CJ, Wong R, Scudera P, Lesser M, DeCosse JJ. Colonic mucosal pH in humans. Dig Dis Sci. 1993;38(3):542鈥?.
  103. Pillay V, Fassihi R. / In vitro release modulation from crosslinked pellets for site specific drug delivery to the gastrointestinal tract I. Comparison of pH-responsive drug release and associated kinetics. J Control Release. 1999;59:229鈥?2.
  104. Pillay V, Fassihi R. / In vitro release modulation from crosslinked pellets for site specific drug delivery to the gastrointestinal tract II. Physicochemical characterization of calcium-alginate, calcium pectinate and calcium-alginate-pectinate pellets. J Control Release. 1999;59:243鈥?6.
  105. Joseph I, Venkataram S. Indomethacin sustained release from alginate-gelatin or pectin-gelatin coacervates. Int J Pharm. 1995;126:161鈥?.
  106. Itoh K, Yahaba M, Takahashi A, Tsuruya R, Miyazaki S, Dairaku M, / et al. In situ gelling xyloglucan/pectin formulations for oral sustained drug delivery. Int J Pharm. 2008;356:95鈥?01.
  107. Nurjaya S, Wong TW. Effects of microwave on drug release properties of matrices of pectin. Carbohydr Polym. 2005;62(3):245鈥?7.
  108. Wong TW, Nurjaya S. Drug release property of chitosan-pectinate beads and its changes under the influence of microwave. Eur J Pharm Biopharm. 2008;69:176鈥?8.
  
• 作者单位：Tin Wui Wong (1) (2) (5)
  Gaia Colombo (3)
  Fabio Sonvico (4)
  
  1. Non-Destructive Biomedical and Pharmaceutical Research Centre, Universiti Teknologi MARA, 42300, Puncak Alam, Selangor, Malaysia
  2. Particle Design Research Group, Faculty of Pharmacy, 42300, Puncak Alam, Selangor, Malaysia
  5. Faculty of Pharmacy, Universiti Teknologi MARA, 42300, Puncak Alam, Selangor, Malaysia
  3. Department of Pharmaceutical Sciences, University of Ferrara, 44100, Ferrara, Italy
  4. Department of Pharmacy, University of Parma, 43100, Parma, Italy
  

文摘

Colon cancer is the fourth most common cancer globally with 639,000 deaths reported annually. Typical chemotherapy is provided by injection route to reduce tumor growth and metastasis. Recent research investigates the oral delivery profiles of chemotherapeutic agents. In comparison to injection, oral administration of drugs in the form of a colon-specific delivery system is expected to increase drug bioavailability at target site, reduce drug dose and systemic adverse effects. Pectin is suitable for use as colon-specific drug delivery vehicle as it is selectively digested by colonic microflora to release drug with minimal degradation in upper gastrointestinal tract. The present review examines the physicochemical attributes of formulation needed to retard drug release of pectin matrix prior to its arrival at colon, and evaluate the therapeutic value of pectin matrix in association with colon cancer. The review suggests that multi-particulate calcium pectinate matrix is an ideal carrier to orally deliver drugs for site-specific treatment of colon cancer as (1) crosslinking of pectin by calcium ions in a matrix negates drug release in upper gastrointestinal tract, (2) multi-particulate carrier has a slower transit and a higher contact time for drug action in colon than single-unit dosage form, and (3) both pectin and calcium have an indication to reduce the severity of colon cancer from the implication of diet and molecular biology studies. Pectin matrix demonstrates dual advantages as drug carrier and therapeutic for use in treatment of colon cancer.